Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety

Next Previous
Trial Profile

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evobrutinib (Primary) ; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms evolutionRMS 1
  • Sponsors Merck KGaA

Most Recent Events

  • 31 May 2024 This study has been completed in Czech Republic (Global end date: 8 Mar 2024).
  • 29 May 2024 This study has been completed in Bulgaria, according to European Clinical Trials Database record.
  • 25 Apr 2024 Status changed from active, no longer recruiting to discontinued. (Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpointof annualized relapse rate for up to 156 weeks compared to oral teriflunomide in both studies.)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top